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Use of Intravenous Gamma Globulin
and Corticosteroids in the Treatment of
Maternal Autoantibody-Mediated Cardiomyopathy
Sara M. Trucco, MD,* Edgar Jaeggi, MD,§ Bettina Cuneo, MD,¶ Anita J. Moon-Grady, MD,*†
Earl Silverman, MD, Norman Silverman, MD,‡ Lisa K. Hornberger, MD*
San Francisco, Sacramento, and Palo Alto, California; Toronto, Ontario, Canada; and Oak Lawn, Illinois
Objectives This study sought to evaluate the outcome of maternal autoantibody-mediated fetal cardiomyopathy/endocar-
dial fibroelastosis following intravenous gamma globulin (IVIG) and corticosteroid therapy.
Background We have previously shown that 85% of fetuses and infants with maternal autoantibody-mediated fetal cardiomy-
opathy/endocardial fibroelastosis suffer demise or need for transplant. In an attempt to improve this outcome,
in 1998, we began to empirically treat affected patients with IVIG and corticosteroids.
Methods We reviewed the clinical records and echocardiograms of 20 affected patients encountered in our institutions
and treated with IVIG and corticosteroids from 1998 to 2009.
Results All 20 were initially referred at a median gestational age of 23 weeks (range 18 to 38 weeks). Nineteen moth-
ers were anti-Ro antibody positive, 8 anti-La antibody positive, and 7 had clinical autoimmune disease. Endocar-
dial fibroelastosis was seen in 16 and was not obvious in 4 others with reduced ventricular function, and 16
(80%) had reduced or borderline ventricular shortening fraction (30%) before or after birth. Eighteen had atrio-
ventricular block at referral (16 in 3°). During pregnancy, maternal IVIG was given in 9 and dexamethasone in
17. After birth, 17 infants received IVIG (n  14) and/or corticosteroids (n  15). Twelve underwent pacemaker
implantation. Four with hydrops at presentation died perinatally, despite initial improvement in function in 3. At
a median follow-up of 2.9 years (1.1 to 9.8 years), 16 (80%) patients are currently alive with normal systolic ven-
tricular function and 6 are not paced.
Conclusions Treatment of maternal autoantibody-mediated fetal cardiomyopathy/endocardial fibroelastosis with IVIG and
corticosteroids potentially improves the outcome of affected fetuses. Further studies are needed to determine
the optimal dose and timing of IVIG administration. (J Am Coll Cardiol 2011;57:715–23) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.0442
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aAnti-Ro(SSA) and anti-La(SSB) antibodies are found in patients
with autoimmune diseases including systemic lupus erythemato-
sus (SLE) and Sjögren syndrome (1), but may also be identified in
regnant women without autoimmune disease (2). Neonatal
upus erythematosus results when these maternal autoantibodies
MAb) pass through the placenta and deposit on fetal tissues,
ncluding the heart (3,4). Clinical fetal myocardial disease is
bserved in 1% to 2% of pregnancies with MAb, typically between
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have reported that they have no relationships to disclose. Thomas P. Graham Jr., MD,
served as a Guest Editor for this paper.d
Manuscript received May 15, 2010; revised manuscript received September 28,
2010, accepted September 29, 2010.0- and 24-weeks gestational age (GA) (5). In most affected
etuses, myocardial damage is largely confined to the conduction
ystem with evolution of atrioventricular block (AVB). Approxi-
ately 20% of affected fetuses, however, can develop more diffuse
yocardial disease manifested as cardiomyopathy (CM) and
sually associated with endocardial fibroelastosis (EFE) (2,6,7),
nd this may occur with or without clinical conduction system
bnormalities. The prognosis for fetuses and infants with diffuse
Ab-CM/EFE is generally poor, with death or need for cardiac
ransplantation in 85% despite successful pacemaker therapy
6–8). A standard treatment approach in pregnancies with MAb-
elated fetal disease, including maternal dexamethasone and beta-
ympathomimetic therapy in conjunction with more aggressive
urveillance and perinatal management, has been shown to
ecrease morbidity and improve outcomes (9). A closer look
t our previous series, however, reveals that fetuses who
eveloped MAb-CM/EFE despite dexamethasone and beta-
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for 80% of all fetal deaths and 44%
of post-natal deaths or cases requir-
ing cardiac transplantation (9).
In 1998, a new treatment strat-
egy of administrating intravenous
gamma globulin (IVIG) and cor-
ticosteroids, either before or after
birth, following a diagnosis of fetal
MAb-CM/EFE was initiated.
Use of IVIG was justified based on
our discovery of diffuse immuno-
globulin (Ig) G deposition, IgM,
and T-cell infiltration throughout
the myocardium, suggesting MAb
induces a fetal immune response
leading to CM/EFE (6,7). In fact,
of the patients with MAb-CM/
EFE described in our previous re-
port (6), the only fetal survivor
received IVIG shortly after birth.
Additionally, the use of IVIG and corticosteroids to treat other
inflammatory disorders, such as SLE and Sjögren syndrome,
has been well described (10,11). We hypothesized that fetuses
and infants with MAb-CM/EFE treated with IVIG and
corticosteroids would have better outcomes than those treated
with corticosteroids alone. This study reports the outcomes of
this novel treatment strategy as experienced in 4 fetal and
neonatal treatment centers with comparison to historical
controls.
Methods
This study was a multicenter, retrospective review that
included patients from the University of California, San
Francisco; the Hospital for Sick Children, Toronto, On-
tario; the University of California, Davis, Sacramento; and
the Heart Institute for Children, Oak Lawn, Illinois. We
included all fetuses and infants of mothers with anti-Ro
and/or anti-La antibodies with evidence of MAb-CM/EFE
defined by the presence of obvious EFE by echocardiogra-
phy and/or myocardial systolic dysfunction. All were treated
with IVIG and corticosteroids before or after birth. Fetuses
and infants with and without AVB and those with simple
congenital heart defects were included. Patients with iso-
lated AVB without CM or EFE, and those with more
complex structural heart disease were excluded.
The clinical presentation, management, and outcome of
20 consecutive cases of MAb-CM/EFE encountered from
1998 to 2009 were reviewed. Clinical data collected in-
cluded GA at diagnosis of fetal heart disease; AVB severity;
timing, type, and dose of therapy; GA at birth; age at
pacemaker insertion, subsequent interventions, and at most
recent follow-up; age at time of death; and cause of death.
Maternal data collected included MAb positivity, presence
Abbreviations
and Acronyms
AVB  atrioventricular
block
CM  cardiomyopathy
DDD  dual mode, dual
pacing, dual sensing
EFE  endocardial
fibroelastosis
GA  gestational age
Ig  immunoglobulin
IVIG  intravenous gamma
globulin
MAb  maternal
autoantibodies
SF  shortening fraction
SLE  systemic lupus
erythematosus
VVI  ventricular inhibitedof clinical autoimmune disease, age at pregnancy, previously aaffected children, and medications and doses received during
pregnancy.
Echocardiographic parameters collected pre-natally in-
cluded atrial and ventricular rates, ventricular systolic func-
tion, severity of tricuspid and mitral insufficiency, and the
presence of any structural heart defects. In cases where the
fetus was not in AVB, the AV interval (reflecting PR
interval) was also measured using previously validated
Doppler techniques (12). Fetal 3° AVB was diagnosed in
cases where there was no mechanical relation between atrial
and ventricular contraction (13). Ventricular shortening
fraction (SF) was calculated with comparison to normal
values and considered abnormal if 28% or borderline in 3°
AVB if 28% to 30% (14). Endocardial fibroelastosis was
suspected when echogenic areas within the endocardium of
atria and ventricles, papillary muscles, and chordae were iden-
tified (6), and it was further categorized by severity (Fig. 1).
ost-natal echocardiograms were also reviewed to document
alve insufficiency, degree and location of EFE, ventricular
unction (SF by M-mode and ejection fraction, available
onsistently in last exam, by biplane Simpson), and presence
f structural heart disease. Autopsy findings were reviewed.
he research ethics boards of the participating institutions
pproved this investigation.
tatistical analysis. Simple statistics were calculated using
icrosoft Excel for Mac (version 11.2.3, Microsoft Corp.,
edmond, Washington).
esults
linical features. Table 1 details the characteristics of the
0 patients encountered. Eighteen were from singleton
regnancies and 2 were dichorionic, diamniotic twins. The
9 pregnancies were diagnosed with fetal cardiac disease at
median GA of 23 weeks (range 18 to 33 weeks). Fetal
chocardiography referral was for fetal bradycardia in 17
85%) and suspected CM/EFE in 3 (15%). Median mater-
al age was 29 years (22 to 38 years). Nineteen mothers
ere anti-Ro and 8 anti-La antibody positive. For one other
ith SLE referred at 38 weeks for delivery, specific antibody
ype was not available. Seven mothers had clinical autoim-
une disease: 5 SLE, 1 hypothyroidism, one rheumatoid
rthritis. Twelve were clinically asymptomatic. One mother
ad a previous infant with AVB.
At initial referral, 16 fetuses had 3° AVB, 1 had 2° AVB,
had 1° AVB, and 2 had a normal atrial rhythm with a
ormal AV interval. Endocardial fibroelastosis was identi-
ed in 16 (13 pre-natally, 3 post-natally) and was consid-
red qualitatively severe in 3, moderate in 6, and mild in 7.
Ab-CM/EFE was suspected in 4 others with myocardial
ystolic dysfunction but without obvious myocardial echo-
enicity. Reduced or borderline left, right, or biventricular
F was present in 11 fetuses at presentation or pre-natal
ollow-up. Five with 3° AVB developed hydrops (2 with
mall effusions, 3 with moderate-large effusions and/or
scites), and 1 in 3° AVB had an isolated pericardial effusion
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February 8, 2011:715–23 IVIG in Immune-Mediated Fetal Cardiomyopathy(Table 1). Five others presented either in the neonatal
period (n  3) or early infancy (n  2) with left ventricular
ystolic dysfunction and symptoms of heart failure.
anagement and clinical outcomes. Pre-natal and post-
atal medical therapies for each patient are described in
able 2. No pregnancy was electively terminated. In 16,
aternal dexamethasone was administered at diagnosis of
VB (n  13) or MAb-CM/EFE (n  3). In another,
rednisone was initially administered for fetal AVB at the
eferring institution, but was replaced with dexamethasone
fter referral to our institution. Two other mothers not
iven dexamethasone were both initially treated at outside
nstitutions and only referred late to our programs. One
atient (#16) developed transient oligohydramnios on dexa-
ethasone that resolved spontaneously by 34 weeks. Dexa-
ethasone therapy was otherwise well tolerated in all
regnancies.
Beta-sympathomimetic therapy was initiated in 9 (47%)
others for fetal ventricular rates of 55 beats/min, myo-
ardial dysfunction, and/or evolving hydrops. Although oral
eta-sympathomimetic therapy was well tolerated, 1 mother
eveloped symptomatic sinus tachycardia (#14) upon con-
ersion to the subcutaneous form, which improved with a
ose reduction from 250 g to 130 g given every 4 h. One
fetus developed ventricular ectopy (#15) that resolved with a
dose reduction, and another developed atrial flutter that
resolved with maternal digoxin (#16).
Intravenous gamma globulin was administered pre-
natally to 9 (47%) mothers at a dose of 70 g (1 g/kg).
Three received a single dose, 3 received 2 pre-natal doses,
and 3 received 3 or more doses. Multiple doses were used in
the setting of worsening or persistent bradycardia and
ventricular dysfunction. Of 9 with maternal IVIG and
corticosteroid therapy, 6 demonstrated improved ventricular
systolic function within 1 to 3 weeks of treatment. In 3
hydropic fetuses, however, improved systolic function and
reduced effusions were only transient (2 to 3 weeks), and 1
demised at 23.5 weeks. Three others without hydrops had
improved function at birth, and in 1, the severity of EFE
lessened (#20). In 2, ventricular SF and EFE severity did
not change through gestation. Four fetuses had improve-
ment in AV conduction (Table 3), all with maternal
dexamethasone and 2 with maternal IVIG therapy. In 2
others with dexamethasone only, AVB progressed.
Fourteen of 19 live-born infants were delivered pre-term
(28.4 to 37 weeks GA). After delivery, 9 had reduced or
borderline ventricular SF. One other was so critically ill, a
post-natal echocardiogram had not been performed prior to
demise. Nine received isuprel for the treatment of severe
bradycardia, and 6 received other medications including
inotropes, bicarbonate, surfactant, and calcium (Table 2).
Twelve neonates (63%) underwent permanent pacemaker
implantation at a median age of 26 h (range 1 h to 7 days),
for dual mode, dual pacing, dual sensing (DDD) (n  4) or
ventricular inhibited (VVI) (n  8) pacing (Table 3). DDDFigure 1 2D Echocardiographic Findings in
2 Fetuses With EFE and Complete Heart Block
(A) Four-chamber view demonstrating subtle echogenicity of the left ventricular
(LV) papillary muscle (free wall) and ventricular septal surface and chordae of
the right ventricle (RV) in a fetus (#14) presenting at 20 weeks. (B) By 29
weeks, fetal hydrops was evolving. The LV was dilated and the RV barely filled.
(C) Severe cardiomegaly demonstrated in a fetus at 32 weeks (#13) associ-
ated with severe biventricular systolic dysfunction and subtle endocardial fibro-
elastosis (EFE). 2D  2-dimensional; LA  left atrium; RA  right atrium.pacing was chosen, particularly in the term neonates to
Pre-Natal Clinical Features of Patients Diagnosed With Maternal Autoantibody-Induced CardiomyopathyTable 1 Pre-Natal Clinical Features of Patients Diagnosed With Maternal Autoantibody-Induced Cardiomyopathy
Case #
Maternal
Diagnosis
Ro/La
Status
GA at Diagnosis
(Referral)
°AVB at
Diagnosis
Atrial:
Ventricular Rate EFE Degree
Initial Fetal SF
RV:LV (%)
Worst Fetal SF
RV:LV (%) Hydrops GA Birth
Worst Post-Natal
LV SF (%)
Pregnancy
Outcome
1 SLE / 25 3° 135:57 Pre: mild 40:40 40:40  35 weeks 20 (NB) Alive
2 Arthritis / 29 3° 130:50 Pre: mild 40:40 40:40  34 weeks 44 (NB) Alive
3 SLE / 21 3° 150:80 Pre: moderate 35:35 35:35  36 weeks 50 (NB) Alive
4 Healthy / 33 3° 150:42 Pre: severe 25:32 20:32  35 weeks 16 (NB) ND
5 Healthy / 21 3° 140:97 None seen 39:40 39:40  34 weeks 20 (NB) Alive
6 SLE / 23 3° 163:63 None seen 41:34 41:34  37 weeks 10 (NB) Alive
7 Healthy / 20 3° 80:52 Pre: severe 25:20 17:20  N/A IUD 23.5 weeks*
8 Healthy / 23 1° 138:138 Pre: mild 15:30 15:30  38 weeks 35 (NB) Alive
9 Healthy / 24 — 150:150 Pre: mild 21:29 21:29  36 weeks 29 (NB) Alive
10 Healthy / 20 2° 150:69 None seen 40:40 40:40  39 weeks 20 (3 months) Alive
11 Healthy / 26 3° 140:65 Post: mild 20:27 20:20  37 weeks 30 (NB) Alive
12† Hypothyroid / 29 (32.5) 3° 110:52 Pre: moderate 20:37 16:31  34 weeks 18 (NB) Alive
13† Hypothyroid / 29 (32.5) 3° 150:74 Post: mild 30:30 28:27  34 weeks 28 (NB) Alive
14 Healthy / 18 (29) 3° 150:32 Pre: moderate 8:8 8:8  31 weeks N/A ND
15 Healthy / 20 3° 138:44 Pre: moderate 30:45 30:45  28.4 weeks 35 (NB) ND
16 Healthy / 18 — 120:120 Pre: moderate 45:45 42:45  34 weeks 35 (NB) Alive
17 Healthy / 23 3° 120:50 Pre: moderate 35:32 33:30  37 weeks 37 (NB) Alive
18 SLE ? 27 (38) 3° ?:60 Post: mild N/A N/A  35 weeks 10 (2 months) Alive
19 Healthy / 21 3° 140:97 None seen 33:30 33:30  34 weeks 28 (NB) Alive
20 SLE / 19 (21) 3° 120:65 Pre: severe 32:34 32:34  38 weeks 35 (NB) Alive
*Gestational age at time of interuterine demise. †Twin gestation, both fetuses affected.
AVB atrioventricular block; EFE endocardial fibroelastosis; GA gestational age; IUD interuterine demise; LV left ventricle; matmaternal; N/A not applicable; NB newborn period; ND neonatal death; post post-natal diagnosis; pre pre-natal diagnosis;
RV  right ventricle; SF  shortening fraction; SLE  systemic lupus erythematosus.
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Pre- and Post-Natal Medical Treatment of Fetuses and Infants With Maternal Autoantibody–Induced CardiomyopathyTable 2 Pre- and Post-Natal Medical Treatment of Fetuses and Infants With Maternal Autoantibody–Induced Cardiomyopathy
Patient #
Pre-Natal
Dexamethasone Dose
(max mg/day) Beta-Sympathomimetics IVIG (GA)
Post-Natal
IVIG Dose and Age Steroids Isuprel Other
1 4 Terbutaline — 1 g/kg at birth Solu-Medrol at birth, prednisone to
3 months
 Dopamine, Lasix, captopril
2 4 Ritodrine — 1 g/kg at 4 days, 4 weeks, 12 weeks Solu-Medrol at birth, prednisone to
3 months
 —
3 8 — 70 g, 1 dose (26 weeks) 1 g/kg at birth Prednisone at birth  —
4 8 Salbutamol — 1 g/kg at birth Prednisone at birth  Milrinone, dopamine
5 8 — — 1 g/kg at birth Prednisone at birth  —
6 8 Salbutamol — 1 g/kg at birth Dexamethasone at birth  —
7 8 Salbutamol 70 g, 2 doses (21, 23 weeks) IUD IUD IUD IUD
8 8 — 70 g, Q 2 wks (23–36 weeks) — Dexamethasone at birth  —
9 8 — 70 g, Q 2 wks (26–39 weeks) — Dexamethasone at birth  —
10 4 — — 1 g/kg at 3 months Solu-Medrol at 3 months  Milrinone, Aldactone, Lasix,
digoxin, carvedilol
11 4 — — 1 g/kg at birth Solu-Medrol at birth  NaHCO3
12 — — — 1 g/kg at birth Solu-Medrol at birth  —
13 — — — 1 g/kg at birth —  —
14 3 Terbutaline* 70 g, 2 doses (25, 28 weeks) — —  Epi, CaCl, NaHCO3, surfactant
15 5 Terbutaline 70 g, 3 doses (20, 23, and 28 weeks) — —  Epi, dop, milrinone, surfactant
16 4 — 70 g, 1 dose (21 weeks) 1 g/kg at 3 months Solu-Medrol at birth  —
17 8 Terbutaline* 70 g, 2 doses (24, 30 weeks) 1 g/kg at birth Solu-Medrol at birth, hydrocortisone to
3 months
 —
18 — — — 1 g/kg at 2 months Solu-Medrol at 2 months  —
19 8 — — 1 g/kg at birth Prednisone at birth  —
20 16 Terbutaline 70 g, 1 dose (25 weeks) — —  —
*Digoxin also given in this pregnancy.
dop  dopamine; epi  epinephrine; IVIG  intravenous gamma globulin; Q  every; other abbreviations as in Table 1.
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mature neonate who arrested pre-operatively had concom-
itant placement of a VVI permanent pacemaker and tem-
porary epicardial atrial and ventricular wires for DDD
pacing. He was DDD paced using the temporary wires for
nearly 2 weeks and converted to VVI mode using the
permanent pacemaker following improvement in ventricular
function. Two patients experienced wound infections, and 1
developed an incisional hernia that required repair.
Eleven neonates received IVIG within the first few days,
and 15 received steroids. In 6, ventricular systolic function
normalized after IVIG and steroid therapy, pacemaker
therapy, and, in 1, coarctation repair (at 3 days, #6). Only 2
required anticongestive therapy at discharge, which was
discontinued within 6 months. Two hydropic fetuses (#14,
#15) demised within the first day despite pre-term delivery
and aggressive resuscitation, and a third (#4) had care
withdrawn for severe neurological injury. Endocardial fibro-
elastosis was confirmed at autopsy in all 3. In 2, diffuse
elastin and collagen deposition in the endocardium was
demonstrated.
Two infants with neonatal pacemaker therapy presented
at 2 to 3 months of age with clinical heart failure (#10, #18).
Both subsequently received IVIG and steroids, and 1 had
device closure of an atrial septal defect and conversion to
biventricular pacing. One other (#16) presented at 2.5
Rhythm and Pacemaker CharacteristicsTable 3 Rhyth and Pacemaker Characteristics
Patient #
°AVB at
Diagnosis Change in Rhythm Neonatal Rhythm
1 3° — 3°
2 3° — 3°
3 3° Reversal to 1°,
intermittent 2°, but
3° by 32 weeks
3°
4 3° — 3°
5 3° Reversal to 1°,
intermittent 2°
1°
6 3° — 3°
7 3° — —
8 1° 1° No AVB
9 — — No AVB
10 2° Intermittent 3° 2°, intermittent 3°
11 3° — 3°
12 3° — 3°
13 3° — 3°
14 3° — —
15 3° — —
16 — — No AVB
17 3° Atrial flutter 3°
18 3° — 3°
19 3° 1° and intermittent 2° 1° and intermittent 2°
20 No AVB 3° by 21 weeks 3°
*Patient with cardiac arrest en route to the operating room necessitating 45-min cardiopulmonar
single-chamber pacemaker. All others had permanent pacemaker insertion at initial operation.
DDD  dual mode, dual pacing, dual sensing; HR  heart rate; VVI  ventricular inhibited; othmonths with acute EFE-related chordal rupture leading tosevere mitral insufficiency and reduced left ventricular sys-
tolic function, as previously reported (15). IVIG and ste-
roids were administered and the infant underwent mitral
valve repair. All 3 had normal ventricular SF within 2 weeks
to 4 months of treatment.
Sixteen (80%) patients are currently alive. None has
required cardiac transplantation. Patient #12 experienced
lead fracture at 15 months necessitating reoperation and had
concomitant suture repair of an atrial septal defect. Another
patient (#12) required pericardiotomy for persistent pericar-
dial effusion after lead replacement at 2 years. At most
recent follow-up (median age: 2.9 years, 1.1 to 9.8 years),
all 16 were found to have normal myocardial function
(left ventricular ejection fraction: median 69%, range 61%
to 73%; shortening fraction: 32%). Six patients are not
paced.
Discussion
This is the first report describing the use of both IVIG and
corticosteroids in the treatment of fetuses and infants with
MAb-CM/EFE. Overall, patient survival was 80%, all with
normal ventricular function at most recent follow-up. This
represents a marked improvement when compared with
historical controls from 3 series where 25 of 32 (78%; range
Pacemaker
Indication
(beats/min)
Neonatal Pacing
Mode Rhythm at Last Follow-Up
cidosis, HR 55 Single-chamber 3° AVB, VVI paced
R 50 Single-chamber 3° AVB, VVI paced
— — 3° AVB, not paced
— — Post-natal death
— — 2° AVB, not paced
R 55 Single-chamber 3°, VVI paced
— — IUD
— — Sinus rhythm, no AVB
— — Sinus rhythm, no AVB
cidosis, HR 60 Dual-chamber 3° AVB, DDD paced
R 55 Single-chamber 3° AVB, VVI paced
cidosis, HR 60* Single-chamber 3° AVB, VVI paced
R 55 Single-chamber 3° AVB, VVI paced
cidosis, HR 55 Single-chamber Post-natal death
cidosis, HR 50 Single-chamber Post-natal death
— — Sinus rhythm, no AVB
R 60 Dual-chamber 3° AVB, DDD paced
R 60 Dual-chamber 3° AVB, DDD, biventricular pacing
— — 1° AVB, not paced
R 55 Dual-chamber 3° AVB, DDD paced
citation. This was the only patient to have temporary pacing as well as placement of permanent
eviations as in Table 1.A
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excluded (6).
MAb-CM/EFE pathogenesis. MAb-CM/EFE is a rare
and poorly understood disorder of the endomyocardium
that can lead to the development of congestive heart failure
and death (6,16,17). Pathologic evaluation reveals collagen
and elastin deposition, ventricular hypertrophy, and diffuse
endocardial thickening (7,18). The finding of MAb-CM/
EFE in the absence of AVB and evolution of late MAb-
CM/EFE despite adequate pacing has suggested that CM/
EFE and AVB may be 2 separate disease manifestations in
neonatal lupus erythematosus (7,8). In general, MAb-
mediated fetal heart disease is believed to be due to the
transplacental passage of MAb anti-Ro and anti-La, which
infiltrate fetal myocardial and specialized conductive tissue,
leading to subsequent inflammation (19). Evidence for an
inflammatory component in the evolution of MAb-CM/
EFE has been demonstrated in autopsy specimens of
patients with AVB who have scattered foci of mononuclear
inflammatory cells and occasional B-cells in the myocar-
dium (7,20). Myocardial IgG and complement deposition
has also been reported (7,21). Interestingly, our previous
discovery of IgM deposition and T-cell foci (CD43 and
CD8 positive cells, T-cell activation) provide further sup-
port for a contributing fetal immune response (6,7). Over
time, these insults may lead to ventricular dilation and
hypertrophy, reduced ventricular compliance, and progres-
sive EFE (22).
Myocardial damage may be clinically manifested with the
development of progressive myocardial dysfunction, which
includes systolic and likely diastolic components. Although
diastolic dysfunction could not be evaluated in the presence
of severe conduction disturbances in the present series, most
had reduced or low-normal (in 3° AVB) SF before and/or
after birth, suggesting systolic dysfunction. In 3° AVB, a
normal cardiac output is maintained through increased
stroke volume, which is likely not possible even with
low-to-normal ventricular systolic function. We had in-
cluded 4 cases with moderate-to-severe EFE but with
normal-to-hyperdynamic ventricular systolic function as
they had been treated with IVIG and corticosteroids in an
effort to prevent the evolution of fetal or post-natal ventric-
ular dysfunction. Although it is not certain these patients
would have had progressive dysfunction, all continue to have
echocardiographic evidence of EFE.
It has been suggested that certain pacemaker strategies
after birth for 3° AVB contribute to the ventricular dysfunc-
tion in MAb-CM/EFE. DDD pacing, for instance, may
not be tolerated particularly where intrinsic sinus rates are
high, leading to detrimentally high ventricular rates (23);
owever, 5 of our patients were at least initially DDD paced
n an effort to provide AV synchrony, and 3 have continued
o be DDD paced longer term without recurrence of
entricular dysfunction. Resynchronization therapy, shown
o be somewhat beneficial for affected infants (23), was used
n 1 of our cases and could have contributed to improved sunction; however, this infant had significant dysfunction
rior to pacing.
VIG in MAb-CM/EFE. Intravenous gamma globulin is
stablished therapy for the treatment of autoimmune and
nflammatory diseases such as SLE and Sjögren syndrome
24,25), and it is commonly used in the treatment of some
ardiac disorders such as inflammatory CM and Kawasaki
isease (26,27). The mode of action of IVIG is still under
nvestigation but is believed to involve Fc-dependent and/or
(ab=)2-dependent nonexclusive mechanisms (11). One an-
mal study showed that maternal administration of IVIG to
nti-Ro and anti-La positive mice significantly reduced the
ransplacental passage of these antibodies by nonspecific
lockade of placental Fc receptors (28). Studies in human
regnancies complicated by SLE (29) or MAb without
linical autoimmune disease but with a prior fetus with
VB (30) have shown normalization or significant reduc-
ion in circulating MAb in response to IVIG. In addition to
educing the ability of MAb to pass through the placenta,
nd reducing overall maternal circulating MAb levels, IVIG
ay also modulate immune system homeostasis through
nteraction with cytokines, complement, and cell surface
mmunocompetent molecules (11) to reduce the fetal
mmune-mediated myocardial damage.
In our experience, IVIG administration in MAb-CM/EFE
s well tolerated. We recognize that maternal IVIG therapy,
owever, is not without risk, as it exposes both mother and
etus to blood products. Intraumbilical administration may
educe maternal exposure, but it is considerably more invasive.
aiting to administer IVIG post-natally, particularly in the
ess-compromised fetus, eliminates maternal exposure risks,
ut subjects the newborn infant to both a blood product and a
arge volume load in the setting of marginal ventricular func-
ion, particularly when the hemodynamic burden of the heart
s already acutely increased with the transition to the neonatal
irculation. More importantly, waiting to provide IVIG until
fter birth may eliminate the added benefits of reducing MAb
xposure and myocardial damage in utero.
examethasone in MAb-CM/EFE. In addition to IVIG,
examethasone was also administered pre-natally to most
others in our series and was largely well tolerated. Prob-
ems with neurodevelopment and growth are potential side
ffects of pre-natal corticosteroid use (31), neither of which
as noted in the clinical records of our patients. We justified
he use of maternal dexamethasone in addition to IVIG for
etal MAb-CM/EFE as we have previously documented
ignificant improvement in the outcomes of isolated fetal
VB (9). Others have also shown improvement in fetal AV
onduction following maternal dexamethasone administra-
ion in incomplete AVB (32), and, in the present report, we
bserved improved AV conduction in 4 pre-natally treated
regnancies. It has been proposed that maternal dexameth-
sone may mitigate the immune-mediated cardiac inflam-
ation provoked by MAb and indirectly improve cardiac
ontractility (33). Dexamethasone is preferable to predni-
one, as prednisone has not been shown to decrease MAb
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
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active drug from entering the fetal circulation (34,35).
Post-natal corticosteroid administration is not without
risk with side effects of systemic hypertension, hyperglyce-
mia, gastrointestinal complications, and impaired immune
function. Two of our patients developed wound infections,
both having received high-dose intravenous Solu-Medrol.
Although we had observed no other potentially steroid-
related complication, we have used lower dose prednisone at
least for less critically ill patients tapering the dose over the
first few months of life.
Study limitations. This study is limited in that it is a
retrospective chart review of patients from multiple centers.
There was no concurrent control group and, as such,
historical controls were used for comparison, which intro-
duces other potential variables in management. The fre-
quency and dosing of IVIG and corticosteroids in mothers
and infants were diverse and left to the discretion of the
treating cardiologist, making it difficult to draw conclusions
regarding optimal timing, dose, and frequency of their use.
Furthermore, although all mothers had documented MAb,
titers were not serially checked, and therefore, the impact of
our treatment strategy on MAb production could not be
assessed. Additionally, structural heart disease requiring surgi-
cal or transcatheter intervention was present in 4 patients, and
the effect of this comorbidity on outcome cannot be assessed.
Finally, EFE was diagnosed by echocardiography and not
histologically; however, in our previous work, EFE detected by
echocardiography consistently underestimated EFE severity
documented pathologically (6,7).
Conclusions
Using IVIG and corticosteroids to treat MAb-CM/EFE
may significantly improve the outcome of this devastating
disease, the exact mechanism of which remains unclear.
Further investigation with a prospective multicenter ran-
domized trial, including the evaluation of maternal and
neonatal titers before and after therapy, is warranted.
However, given that this is a rare disease with a high
morbidity and mortality, a randomized trial may continue to
prove impractical.
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